---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Effect on quality measures"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Effect on quality measures. Topics: Hospital Harm, Severe Hypoglycemia electronic clinical quality measure (context; counts only events after a hypoglycemic medication); Hospital Harm, Severe Hypoglycemia electronic clinical quality measure: rationale. 2 evidence topics quoted from 1 source."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/effect-on-quality-measures"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Effect on quality measures

<a id="heading-2.1.2.13"></a>

## 2.1.2.13 Effect of Ersodetug on Quality Measures

<a id="topic-2.1.2.13-1"></a>

### Hospital Harm, Severe Hypoglycemia electronic clinical quality measure (context; counts only events after a hypoglycemic medication)

| Field | CMS816v5 |
| --- | --- |
| Short name | “HH-Hypo” |
| Measure steward | “Centers for Medicare & Medicaid Services (CMS)” |
| Description | “The measure assesses the number of inpatient hospitalizations for patients age 18 and older who were administered at least one hypoglycemic medication during the encounter and who suffer the harm of a severe hypoglycemic event during the encounter” |
| Measure type | “Outcome” |
| Initial population | “Inpatient hospitalizations that end during the measurement period for patients age 18 and older and at least one hypoglycemic medication administration starts during the encounter” |
| Numerator | “Inpatient hospitalizations where a severe hypoglycemic event occurred during the encounter” |

Source: [eCQI Resource Center CMS816v5 (2026)](https://ecqi.healthit.gov/ecqm/hosp-inpt/2026/cms0816v5)

<a id="topic-2.1.2.13-2"></a>

### Hospital Harm, Severe Hypoglycemia electronic clinical quality measure: rationale

> “Inpatient hypoglycemia can be life-threatening, and is associated with longer hospital stays and increased medical costs.”
> “Severe hypoglycemia (<40 mg/dL) occurs in 2–5% of hospitalized patients with diabetes mellitus, and medication-related hypoglycemic events are common causes of adverse drug events occurring in inpatient settings.”
> “Rates of inpatient hypoglycemia events are considered an indicator of the quality of care provided by a hospital.”
> “Severe hypoglycemia events are largely avoidable by careful use of antihyperglycemic medication.”

Source: [eCQI Resource Center CMS816v5 (2026)](https://ecqi.healthit.gov/ecqm/hosp-inpt/2026/cms0816v5)

<a id="topic-2.1.2.13-3"></a>

### Product-specific effect on quality measures

No evidence found.

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
